BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression

V. Nociti, M. Santoro, D. Quaranta, F.A. Losavio, C. De Fino, R. Giordano, N. Palomba, P.M. Rossini, F.R. Guerini, M. Clerici, D. Caputo, M. Mirabella

Research output: Contribution to journalArticle

Abstract

Introduction Brain-Derived Neurotrophic Factor (BDNF) and its most common polymorphism Val66Met are known to have a role in Multiple Sclerosis (MS) pathogenesis. Evidence is accumulating that there is an involvement of DNA methylation in the regulation of BDNF expression. The aim of this study was to assess in blood samples of MS patients the correlation between the methylation status of the CpG site near BDNF-Val66Met polymorphism and the severity of the disease. Methods We recruited 209 MS patients that were genotyped for the BDNF Val66Met polymorphism. For each patient we quantitatively measured the methylation level of cytosine included in the exonic CpG site that can be created or abolished by the Val66Met BDNF polymorphism. Furthermore, we analyzed the clinical history of each patient and determined the time elapsed since the onset of the disease and an EDSS score of 6.0. Results The genetic analysis identified 122 (58.4%) subjects carrying the Val/Val genotype, 81 (38.8%) with Val/Met genotype, and 6 (2.8%) carrying the Met/Met genotype. When the endpoint of an EDSS score of 6 was taken into account by means of a survival analysis, 52 failures (i.e., reaching an EDSS score of 6) were reported. When the sample was stratified according to the percentage of the BDNF methylation, subjects falling below the median (median methylation = 81%) were at higher risk of failure (IRD = 0.016; 95%CI = 0.0050- 0.0279; p = 0.004). Conclusions In patients with a high disease progression the hypomethylation of the BDNF gene could increase the secretion of the protective neurotrophin, so epigenetic modifications could be the organism response to limit a brain functional reserve loss. Our study suggests that the percentage of methylation of the BDNF gene could be used as a prognostic factor for disease progression toward a high disability in MS patient. © 2018 Nociti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.
Original languageEnglish
JournalPLoS One
Volume13
Issue number10
DOIs
Publication statusPublished - 2018

Fingerprint

neurotrophins
Methylation
Brain-Derived Neurotrophic Factor
sclerosis
Polymorphism
disease course
methylation
Multiple Sclerosis
Disease Progression
genetic polymorphism
brain
Genotype
Accidental Falls
Genes
genotype
Cognitive Reserve
Cytosine
Nerve Growth Factors
DNA Methylation
Licensure

Keywords

  • brain derived neurotrophic factor
  • cytosine, adult
  • Article
  • BDNF gene
  • blood sampling
  • correlational study
  • CpG island
  • disease exacerbation
  • disease severity
  • DNA methylation
  • female
  • gene
  • gene identification
  • genetic analysis
  • genotype
  • human
  • major clinical study
  • male
  • middle aged
  • multiple sclerosis
  • quantitative analysis
  • scoring system
  • single nucleotide polymorphism
  • survival analysis

Cite this

BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression. / Nociti, V.; Santoro, M.; Quaranta, D.; Losavio, F.A.; De Fino, C.; Giordano, R.; Palomba, N.; Rossini, P.M.; Guerini, F.R.; Clerici, M.; Caputo, D.; Mirabella, M.

In: PLoS One, Vol. 13, No. 10, 2018.

Research output: Contribution to journalArticle

Nociti, V. ; Santoro, M. ; Quaranta, D. ; Losavio, F.A. ; De Fino, C. ; Giordano, R. ; Palomba, N. ; Rossini, P.M. ; Guerini, F.R. ; Clerici, M. ; Caputo, D. ; Mirabella, M. / BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression. In: PLoS One. 2018 ; Vol. 13, No. 10.
@article{2e2ab5c076bb40d48a7767db9b1a81f9,
title = "BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression",
abstract = "Introduction Brain-Derived Neurotrophic Factor (BDNF) and its most common polymorphism Val66Met are known to have a role in Multiple Sclerosis (MS) pathogenesis. Evidence is accumulating that there is an involvement of DNA methylation in the regulation of BDNF expression. The aim of this study was to assess in blood samples of MS patients the correlation between the methylation status of the CpG site near BDNF-Val66Met polymorphism and the severity of the disease. Methods We recruited 209 MS patients that were genotyped for the BDNF Val66Met polymorphism. For each patient we quantitatively measured the methylation level of cytosine included in the exonic CpG site that can be created or abolished by the Val66Met BDNF polymorphism. Furthermore, we analyzed the clinical history of each patient and determined the time elapsed since the onset of the disease and an EDSS score of 6.0. Results The genetic analysis identified 122 (58.4{\%}) subjects carrying the Val/Val genotype, 81 (38.8{\%}) with Val/Met genotype, and 6 (2.8{\%}) carrying the Met/Met genotype. When the endpoint of an EDSS score of 6 was taken into account by means of a survival analysis, 52 failures (i.e., reaching an EDSS score of 6) were reported. When the sample was stratified according to the percentage of the BDNF methylation, subjects falling below the median (median methylation = 81{\%}) were at higher risk of failure (IRD = 0.016; 95{\%}CI = 0.0050- 0.0279; p = 0.004). Conclusions In patients with a high disease progression the hypomethylation of the BDNF gene could increase the secretion of the protective neurotrophin, so epigenetic modifications could be the organism response to limit a brain functional reserve loss. Our study suggests that the percentage of methylation of the BDNF gene could be used as a prognostic factor for disease progression toward a high disability in MS patient. {\circledC} 2018 Nociti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.",
keywords = "brain derived neurotrophic factor, cytosine, adult, Article, BDNF gene, blood sampling, correlational study, CpG island, disease exacerbation, disease severity, DNA methylation, female, gene, gene identification, genetic analysis, genotype, human, major clinical study, male, middle aged, multiple sclerosis, quantitative analysis, scoring system, single nucleotide polymorphism, survival analysis",
author = "V. Nociti and M. Santoro and D. Quaranta and F.A. Losavio and {De Fino}, C. and R. Giordano and N. Palomba and P.M. Rossini and F.R. Guerini and M. Clerici and D. Caputo and M. Mirabella",
note = "cited By 0",
year = "2018",
doi = "10.1371/journal.pone.0206140",
language = "English",
volume = "13",
journal = "PLoS One",
issn = "1932-6203",
publisher = "Public Library of Science",
number = "10",

}

TY - JOUR

T1 - BDNF rs6265 polymorphism methylation in Multiple Sclerosis: A possible marker of disease progression

AU - Nociti, V.

AU - Santoro, M.

AU - Quaranta, D.

AU - Losavio, F.A.

AU - De Fino, C.

AU - Giordano, R.

AU - Palomba, N.

AU - Rossini, P.M.

AU - Guerini, F.R.

AU - Clerici, M.

AU - Caputo, D.

AU - Mirabella, M.

N1 - cited By 0

PY - 2018

Y1 - 2018

N2 - Introduction Brain-Derived Neurotrophic Factor (BDNF) and its most common polymorphism Val66Met are known to have a role in Multiple Sclerosis (MS) pathogenesis. Evidence is accumulating that there is an involvement of DNA methylation in the regulation of BDNF expression. The aim of this study was to assess in blood samples of MS patients the correlation between the methylation status of the CpG site near BDNF-Val66Met polymorphism and the severity of the disease. Methods We recruited 209 MS patients that were genotyped for the BDNF Val66Met polymorphism. For each patient we quantitatively measured the methylation level of cytosine included in the exonic CpG site that can be created or abolished by the Val66Met BDNF polymorphism. Furthermore, we analyzed the clinical history of each patient and determined the time elapsed since the onset of the disease and an EDSS score of 6.0. Results The genetic analysis identified 122 (58.4%) subjects carrying the Val/Val genotype, 81 (38.8%) with Val/Met genotype, and 6 (2.8%) carrying the Met/Met genotype. When the endpoint of an EDSS score of 6 was taken into account by means of a survival analysis, 52 failures (i.e., reaching an EDSS score of 6) were reported. When the sample was stratified according to the percentage of the BDNF methylation, subjects falling below the median (median methylation = 81%) were at higher risk of failure (IRD = 0.016; 95%CI = 0.0050- 0.0279; p = 0.004). Conclusions In patients with a high disease progression the hypomethylation of the BDNF gene could increase the secretion of the protective neurotrophin, so epigenetic modifications could be the organism response to limit a brain functional reserve loss. Our study suggests that the percentage of methylation of the BDNF gene could be used as a prognostic factor for disease progression toward a high disability in MS patient. © 2018 Nociti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

AB - Introduction Brain-Derived Neurotrophic Factor (BDNF) and its most common polymorphism Val66Met are known to have a role in Multiple Sclerosis (MS) pathogenesis. Evidence is accumulating that there is an involvement of DNA methylation in the regulation of BDNF expression. The aim of this study was to assess in blood samples of MS patients the correlation between the methylation status of the CpG site near BDNF-Val66Met polymorphism and the severity of the disease. Methods We recruited 209 MS patients that were genotyped for the BDNF Val66Met polymorphism. For each patient we quantitatively measured the methylation level of cytosine included in the exonic CpG site that can be created or abolished by the Val66Met BDNF polymorphism. Furthermore, we analyzed the clinical history of each patient and determined the time elapsed since the onset of the disease and an EDSS score of 6.0. Results The genetic analysis identified 122 (58.4%) subjects carrying the Val/Val genotype, 81 (38.8%) with Val/Met genotype, and 6 (2.8%) carrying the Met/Met genotype. When the endpoint of an EDSS score of 6 was taken into account by means of a survival analysis, 52 failures (i.e., reaching an EDSS score of 6) were reported. When the sample was stratified according to the percentage of the BDNF methylation, subjects falling below the median (median methylation = 81%) were at higher risk of failure (IRD = 0.016; 95%CI = 0.0050- 0.0279; p = 0.004). Conclusions In patients with a high disease progression the hypomethylation of the BDNF gene could increase the secretion of the protective neurotrophin, so epigenetic modifications could be the organism response to limit a brain functional reserve loss. Our study suggests that the percentage of methylation of the BDNF gene could be used as a prognostic factor for disease progression toward a high disability in MS patient. © 2018 Nociti et al. This is an open access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are credited.

KW - brain derived neurotrophic factor

KW - cytosine, adult

KW - Article

KW - BDNF gene

KW - blood sampling

KW - correlational study

KW - CpG island

KW - disease exacerbation

KW - disease severity

KW - DNA methylation

KW - female

KW - gene

KW - gene identification

KW - genetic analysis

KW - genotype

KW - human

KW - major clinical study

KW - male

KW - middle aged

KW - multiple sclerosis

KW - quantitative analysis

KW - scoring system

KW - single nucleotide polymorphism

KW - survival analysis

U2 - 10.1371/journal.pone.0206140

DO - 10.1371/journal.pone.0206140

M3 - Article

VL - 13

JO - PLoS One

JF - PLoS One

SN - 1932-6203

IS - 10

ER -